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Objectives. We tested the hypothesis that angiotensin-
converting enzyme (ACE) inhibitor therapy decreases left ventric-
ular (LV) mass in patients with a left ventricular ejection fraction
(LVEF) >40% and no evidence of heart failure after their first
acute Q wave myocardial infarction (MI).
Background. Recently, ACE inhibitor therapy has been shown
to have an early mortality benefit in unselected patients with acute
MI, including patients without heart failure and a LVEF >35%.
However, the effects on LV mass and volume in this patient
population have not been studied.
Methods. Thirty-five patients with a LVEF >40% after their
first acute Q wave MI were randomized to titrated oral ramipril
(n 5 20) or conventional therapy (control, n 5 15). Magnetic
resonance imaging (MRI) performed an average of 7 days and 3
months after MI provided LV volumes and mass from summated
serial short-axis slices.
Results. Left ventricular end-diastolic volume index did not
change in ramipril-treated patients (62 6 16 [SD] to 66 6
17 ml/m2) or in control patients (62 6 16 to 68 6 17 ml/m2), and
stroke volume index increased significantly in both groups. How-
ever, LV mass index decreased in ramipril-treated patients (82 6
18 to 73 6 19 g/m2, p 5 0.0002) but not in the control patients
(77 6 15 to 79 6 23 g/m2). Systolic arterial pressure did not
change in either group at 3-month follow-up.
Conclusions. In patients with a LVEF >40% after acute MI,
ramipril decreased LV mass, and blood pressure and LV function
were unchanged after 3 months of therapy. Whether the decrease
in mass represents a sustained effect that is associated with a
decrease in morbid events requires further investigation.
(J Am Coll Cardiol 1997;29:49–54)
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Large trials have demonstrated a significant reduction in
cardiovascular morbidity and mortality with long-term use of
angiotensin-converting enzyme (ACE) inhibitors in patients
with left ventricular (LV) dysfunction, heart failure or acute
myocardial infarction (MI), or a combination of these (1–3).
This benefit included an;24% reduction in the risk of MI, the
need for revascularization and a reduction in the likelihood of
hospital admission for unstable angina. This effect was inde-
pendent of LV ejection fraction (LVEF) and greater than
expected for the small reduction in blood pressure (1). The
recent Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico (GISSI-3) and Fourth International
Study of Infarct Survival (ISIS-4) results have demonstrated a
mortality benefit of ACE inhibitor therapy in unselected
patients, including patients without LV dysfunction (4,5).
Furthermore, captopril had a favorable effect on ischemic
burden and functional capacity, as well attenuation of LV
dilation in post-MI patients with only mild LV dysfunction (6).
Taken together, these studies suggest that ACE inhibitor
therapy benefits a wider group of post-MI patients, including
those with well-preserved LV function.
The effects of ACE inhibitors on LV function have been
extensively studied in selected patients with documented LV
dysfunction (LVEF,40%). Therapy with ACE inhibitors have
been shown to attenuate the increase in LV volumes, to
decrease myocardial mass and to preserve LVEF (7–13).
These beneficial effects of ACE inhibitors in patients with LV
dysfunction are presumably mediated by decreasing preload
and afterload, but ACE inhibitor therapy may also exert tissue
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effects on the myocardium and vasculature by blunting the
trophic effect of angiotensin II on myocytes and fibroblasts in
the heart (14,15) and by preventing the degradation of endog-
enous kinins (e.g., bradykinin) to inactive metabolites (16,17).
The impetus for the current investigation was generated
because of the ongoing large-scale clinical trials evaluating the
prevention of atherosclerosis-related events using ACE inhib-
itors in all patients with coronary artery disease, including
those with well-preserved LV function (18). The Survival And
Ventricular Enlargement (SAVE) trial included patients with
LVEF ,40%; however, no study has evaluated the effects of
ACE inhibitors on LV mass and volumes in patients with
preserved LV function (LVEF .40%) and coronary athero-
sclerosis. Thus, the current investigation examines the effects
of the ACE inhibitor ramipril on LV volumes and mass in
patients with LVEF .40% after acute MI using geometry-
independent calculations of mass and volume from summated
serial short-axis slices obtained from magnetic resonance im-
aging (MRI).
Methods
Patient selection. Forty-four patients who had their first
acute Q wave MI and had a LVEF .40% were enrolled
between April 1993 and September 1994. All patients were in
normal sinus rhythm and had evidence of an acute transmural
MI with new abnormal Q waves in at least two contiguous
electrocardiographic (ECG) leads, ST segment elevation
$2 mm above baseline in at least two contiguous ECG leads,
creatine kinase–MB isoenzyme elevation and a clinical history
of angina lasting longer than 30 min. Exclusion criteria in-
cluded previously documented MI, presence of significant
valvular heart disease, symptomatic congestive heart failure,
atrial fibrillation, suspected renal artery stenosis, renal insuf-
ficiency with serum creatinine .2.0 mg/dl, child-bearing po-
tential, prior use or known allergy to ACE inhibitors and any
contraindication to MRI. Conventional therapy, thrombolytic
agents or primary percutaneous transluminal coronary angio-
plasty (PTCA), nitrates, beta-blockers, calcium entry blockers
and revascularization were offered to all patients as deter-
mined by their primary physician. Before entry into the
research protocol, each potential subject signed an informed
consent and underwent a history and physical examination
conducted by one of the investigators. Subsequently, initial
MRI was performed in each patient within 16 days of acute MI.
This protocol was reviewed and approved by the Institutional
Review Board for Human Use at the University of Alabama,
Birmingham.
Magnetic resonance imaging. MRI was performed using a
1.5-tesla nuclear MRI/spectroscopy system (ACS Philips) using
a gradient echocardiographic imaging approach acquiring se-
rial short-axis slices of 8 mm thickness with a slice gap of
1.0 mm as previously described in our laboratory (19,20). The
MASS version 1.0 cardiac software package (Laboratory of
Clinical and Experimental Imaging Processing, University
Hospital at Leiden) was used to measure LVEF, LV volumes
and LV mass from the summated serial short-axis slices using
the Simpson rule as previously validated in our laboratory
(19,20). Circumferential wall thickness was assessed at the base
of the heart from a slice that was not involved in the MI.
Assessment of the MRI scans was performed by a technician
(R.O.) who had no knowledge of the patients’ treatment
group.
Randomization and treatment. After documenting a
LVEF .40% by MRI, patients were randomized to conven-
tional therapy as dictated by their primary physician or con-
ventional therapy plus titrated dose ramipril. All patients were
evaluated by a history and physical examination by one of the
investigators at baseline, at 2 weeks and at 3 months after their
MI. An ECG, blood urea nitrogen and creatinine levels,
urinalysis and a complete blood cell count were obtained at
these visits. All patients in both groups had their blood
pressure measured by a physician every 7 days for 2 weeks after
discharge. All patients randomized to receive ramipril were
started on 2.5 mg twice daily and titrated upward to 5 mg and
then to 10 mg twice daily at 7 and 14 days if systolic blood
pressure remained.110 mmHg. The same approach was used
in the patients receiving conventional therapy with nitrates,
beta-blockers and calcium channel blocking drugs. The starting
dose of 2.5 mg of ramipril was chosen based on the docu-
mented effect of this oral dose in decreasing cardiac ACE
activity by 35% in tissue extracts of human hearts obtained at
the time of surgery (21).
Data analysis. The data are presented as mean value 6
SD. Differences in baseline characteristics, hemodynamic vari-
ables and LV volumes and LV mass were determined by the
unpaired Student t test. Baseline and 3-month follow-up data
were analyzed using the paired Student t test. Although this is
a randomized trial, the degree of change for any given variable
may be correlated with the magnitude of baseline hemody-
namic variables and LV volume and mass values and with
other factors, including age, gender, history of hypertension,
location of MI and use of thrombolytic therapy. Therefore, the
significance of treatment effect (ramipril vs. conventional
therapy) was determined by analysis of covariance, adjusting
for potential baseline differences between the groups. The
covariates included those listed in Tables 1 and 2. Because of
the small sample size, potential covariates were determined by
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
GISSI 5 Gruppo Italiano per lo Studio della Streptochinasi
nell’Infarto Miocardico
ISIS 5 International Study of Infarct Survival
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backward stepwise regression with p# 0.10. Any change in LV
mass or volume during the study was then adjusted for the
significant covariates. These adjusted changes were considered
significant between the two groups with p , 0.05.
Results
Patient group (Table 1). Forty-four patients underwent
baseline MRI and randomization at a mean of 7 6 4 days
(range 2 to 16) after their MI. Twenty-one patients were
randomized to conventional therapy and 23 to conventional
therapy plus ramipril. Thirty-five patients completed their
baseline and 3-month follow-up MRI studies. Three patients
receiving ramipril did not complete the study: one developed
angioedema, one developed hyperkalemia and one had persis-
tent nausea. A control patient was inadvertently started on an
ACE inhibitor by the clinic physician and was therefore
excluded from the study. Five control patients did not com-
plete the study owing to their refusal to return for the final
MRI study. Patients who did not have the 3-month MRI study
were omitted from the analysis.
The baseline clinical data for patients completing the study
are presented in Table 1. There were no significant differences
between treatment groups regarding age, gender, history of
hypertension and angina, MI location, use of thrombolysis/
PTCA or concomitant drug therapy. Ramipril was initiated
within an average of 7 days of MI, and after 3 months of
therapy the titrated mean dose of ramipril was 7 mg/d (range
of 1.25 to 10). Coronary angiography was performed in 87% of
the patients who had conventional therapy and in all ramipril-
treated patients at the discretion of the primary physician as
part of post-MI risk stratification. Patency of the infarct-
related artery was documented in 92% and 95% of the
conventional therapy and ramipril-treated groups, respectively,
as a result of thrombolysis or PTCA, or both. The extent of
coronary artery disease in the ramipril-treated patients (de-
fined as diameter stenosis .70%) was single-vessel (55%),
two-vessel (30%) and three-vessel (10%) disease and no
significant disease (5%). The extent of coronary artery disease
in the patients who had conventional therapy (defined as
diameter stenosis .70%) was single-vessel (69%), two-vessel
(15%) and three-vessel (8%) disease and no significant disease
(8%).
Hemodynamic variables and volumes and mass (Table 2).
At the time of randomization there were no differences in
heart rate or systemic arterial pressure between the control
and ramipril groups. Although there was no significant change
in systolic blood pressure from baseline to the 3-month
follow-up in either group, systolic blood pressure was greater
in the control versus the ramipril-treated patients at 3-month
follow-up (128 6 13 vs. 118 6 13 mm Hg, p 5 0.02). Baseline
LVEF, end-diastolic volume index, end-systolic volume index
and mass index did not differ between the control and ramipril
groups. In patients treated with conventional therapy alone,
LV end-diastolic volume index, mass index, mean circumfer-
ential wall thickness and mass to end-diastolic volume ratio
remained unchanged. However, LVEF increased from the
baseline to the 3-month follow-up study.
Patients treated with conventional therapy plus ramipril
demonstrated no change in LV end-diastolic volume index or
end-systolic volume index. However, LV mass index and mean
circumferential wall thickness of noninfarcted myocardium
decreased significantly with ramipril therapy (Fig. 1). The
decrease in LV mass was accompanied by a decrease in mass to
end-diastolic volume ratio. The decrease in LV mass index,
mean circumferential wall thickness and mass to end-diastolic
volume ratio in the ramipril-treated group persisted after
performing analysis of covariance, adjusting for potential
differences in baseline patient characteristics (Table 1), hemo-
dynamic variables and LV mass and volumes (Table 2) in both
groups.
The percent change in LV end-diastolic volume index, mass
index and mass to end-diastolic volume ratio for the ramipril
and control groups is depicted in Figure 2. Left ventricular
Table 2. Hemodynamic and Left Ventricular Volume Data
Variable
Control (n 5 15) Ramipril (n 5 20)
Baseline 3 mo Baseline 3 mo
SBP (mm Hg) 120 6 16 128 6 13 123 6 13 118 6 13
DBP (mm Hg) 76 6 8 78 6 7 74 6 8 70 6 10
HR (beats/min) 76 6 10 69 6 12 75 6 9 72 6 11
LVEDVI (ml/m2) 62 6 16 68 6 17 62 6 16 66 6 17
LVESVI (ml/m2) 30 6 10 30 6 14 32 6 12 33 6 13
SVI (ml/m2) 32 6 7 38 6 4† 30 6 6 33 6 7*
LVEF (%) 52 6 6 57 6 8* 50 6 8 52 6 9
LV mass index (g/m2) 77 6 15 79 6 23 82 6 18 73 6 19†
LV wall thickness (cm) 1.15 6 0.18 1.10 6 0.21 1.14 6 0.14 1.00 6 0.12†
LV mass/LVEDV ratio 1.30 6 0.37 1.17 6 0.27 1.34 6 0.21 1.13 6 0.24†
*p , 0.05. †p , 0.005. Data are presented as mean value 6 SD. DBP 5
diastolic blood pressure; HR 5 heart rate; LVEDVI 5 left ventricular end-
diastolic volume index; LVEF 5 left ventricular ejection fraction; LVESVI 5
left ventricular end-systolic volume index; SBP 5 systolic blood pressure; SVI 5
stroke volume index.
Table 1. Baseline Patient Characteristics
Variable Control (n 5 15) Ramipril (n 5 20)
Age (mean 6 SD, yr) 60 6 11 58 6 11
Gender (male/female) 13/2 18/2
HTN 4 (27) 5 (25)
Angina 2 (13) 3 (15)
Anterior MI 6 (40) 11 (55)
Inferior MI 9 (60) 9 (45)
Beta-blockers 12 (80) 15 (75)
Nitrates 13 (86) 16 (80)
Calcium entry blockers 1 (7) 0
Thrombolytic agents 9 (60) 10 (50)
Open infarct-related artery 12 (92) 19 (95)
PTCA 9 (60) 16 (80)
CABG 0 1 (5)
Data presented are number (%) of patients, unless otherwise indicated.
CABG 5 coronary artery bypass grafting; HTN 5 hypertension; MI 5 myocar-
dial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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mass decreased significantly in the ramipril group (10%, p ,
0.001) and did not change in the conventional therapy group
(2%). Thus, the decrease in the mass to end-diastolic volume
ratio in the ramipril-treated patients was mediated by the
decrease in LV mass rather than by an increase in end-diastolic
volume.
Discussion
In the current investigation, patients with a LVEF .40%
after their first acute Q wave MI were randomized to conven-
tional therapy or conventional therapy plus ramipril. Ramipril
decreased LV wall thickness and mass, whereas LV volumes
and blood pressure did not change in either group. The
changes in mass and wall thickness with ramipril persisted after
analysis of covariance, correcting for any potential baseline
differences in patient characteristics, hemodynamic variables
and LV mass and volumes. To our knowledge, this is the first
investigation to evaluate the effects of ACE inhibitor therapy
on LV volumes and mass in patients with well-preserved LV
systolic function after MI.
Results of the current study. Our patients did not have
increased LV mass or systolic hypertension at baseline. This
may reflect the low incidence of hypertension and the frequent
use of nitrate and beta-blocker therapy in our patients.
Ramipril therapy decreased LV mass by 11% and wall thick-
ness of noninfarcted myocardium by 9% in our post-MI
patients, despite a lack of change in blood pressure. These
relatively small changes in LV mass and wall thickness are
within the resolution of the images obtained by MRI and can
be obtained with high interobserver and intraobserver repro-
ducibility (22). With regard to LV mass determination, the
post-MI ventricle does not conform to simple geometry owing
to the presence of regional ischemia or infarction, or both.
Magnetic resonance imaging can be used to tomographically
section the entire heart, providing accurate measurements of
ventricular volume and mass, as well as wall thickness inde-
pendent of geometric assumptions (19,20).
The decrease in LV mass, without significantly changing
systolic pressure, is in keeping with studies of pressure over-
load in the rat, which demonstrated hypertrophy regression
without changes in carotid (23,24) or LV systolic pressure
(25,26), suggesting a tissue effect of ACE inhibitors. In our
patients, however, a late systolic pressure peak at the root of
the aorta from reflected waves may have been moderated by
ACE inhibitor therapy, thus decreasing afterload not detected
in the simple measurement of blood pressure (27). Further-
more, a single measurement of blood pressure at one point in
time may not provide an overall impact of these agents on
ventricular afterload over the 3-month follow-up period. Al-
though there are no data in normal human subjects, ACE
inhibitor therapy has been demonstrated to decrease LV mass
in the normal rat (28–31). In these studies, the decrease in LV
mass was proportional to the decrease in blood pressure,
suggesting that the normal left ventricle is capable of down-
ward regulation of its mass in response to a reduced hemody-
Figure 2. Bar graph depicting the changes in left ventricular end-
diastolic volume index (LVEDVI), LV mass index and LV mass/end-
diastolic volume (EDV) ratio in control and ramipril-treated groups.
(See text for details.) *p , 0.001 for change compared with baseline.
Figure 1. Long-axis (A) and short-axis (B) end-diastolic and end-
systolic magnetic resonance images of the heart at baseline and 3
months after an anterior myocardial infarction in a patient randomized
to receive ramipril. There is decreased wall thickening in the interven-
tricular septum on the short-axis images. Note the decrease in LV wall
thickness in noninfarcted myocardium at end-diastole, the increase in
LV end-diastolic chamber size and the decrease in the LV mass/end-
diastolic volume ratio as systolic wall thickening remains well pre-
served at the 3-month study in both long- and short-axis images.
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namic load. In support of this mechanism, the lower systolic
blood pressure achieved in patients receiving ramipril versus
conventional therapy alone could explain the decrease in LV
mass in the ramipril-treated patients. However, our patients
had an acute MI, and whether this provides a stimulus for
hypertrophy in noninfarcted myocardium in the early post-MI
period, even when LV function is well preserved, remains an
open question.
Results of other work. Gintzon et al. (32) demonstrated a
significant increase in LV mass of noninfarcted myocardium in
patients with both small and large MIs over a 9-month period
of observation. In addition, McDonald et al. (33) demon-
strated a 22% increase in LV mass in dogs 1 week after
experimentally induced myocardial damage involving only
17% of the myocardium. Kramer et al. (34) reported a 43%
increase in LV mass 1 week after 26% myocardial damage in
sheep. These last two animal studies demonstrate an early
hypertrophic response within 1 week after small- to moderate-
sized MIs.
The mechanical stimulus for hypertrophy in small- to
moderate-sized MIs could result from elevated diastolic filling
pressures. Gottlieb et al. (35) demonstrated that approximately
half of the patients who presented with mild to moderate
pulmonary congestion had LVEFs .40%. In addition, previ-
ous studies demonstrated that patients with an acute MI had
marked activation of all neurohormonal systems, many of
which are growth factors (36). Plasma renin and angiotensin II
levels were shown to increase twofold on the third day after MI
in patients without heart failure (37). Furthermore, rat models
of MI demonstrated increased ACE activity and ACE gene
transcript levels in noninfarcted myocardium in small and large
MIs (38). Taken together, increases in diastolic load as well as
circulating and local neurohormonal factors could stimulate
hypertrophy in noninfarcted myocardium within 1 week after
MI.
Whether there was an actual increase in wall thickness in
noninfarcted myocardium after MI that was reversed by
ramipril and whether a decrease from a normal LV mass and
wall thickness represent a beneficial effect cannot be answered
by this study. In ramipril-treated patients, LVEF remained
unchanged despite the decrease in mass/volume ratio. In
contrast, echocardiographic studies in humans (32) and dogs
(39) after MI have suggested that hypertrophy in the nonin-
farcted myocardium normalizes wall stress and has a beneficial
effect on LV function. However, in the rat model of MI, there
is increased collagen accumulation (40), decreased capillary
density (41) and altered epicardial to endocardial flow ratios
(42) in noninfarcted myocardium, suggesting that this process
represents a “pathologic” hypertrophy that may result in
long-term LV dysfunction. Therapy with ACE inhibitors in rats
with experimentally induced MI decreases LV mass, preserves
function and prolongs survival compared with untreated rats
(43–46).
Conclusions. Reductions in acute ischemic events (e.g.,
MI, unstable angina and need for revascularization) in the
Studies of Left Ventricular Dysfunction (SOLVD) and the
SAVE trials were independent of LVEF in patients treated
with ACE inhibitors (15). In addition, the mortality benefit of
ACE inhibitor therapy in the unselected patient groups of
GISSI-3 and ISIS-4 included patients with well-preserved LV
function. Our results must be interpreted with caution owing to
the small number of patients studied. Furthermore, it is
questionable whether there is any benefit from the small
decrease in LV mass in our patients because there was
relatively little evidence of LV remodeling, as demonstrated by
no change in LV volume and LVEF in both groups receiving
standard therapy after MI. This finding may be related to a
patent infarct-related artery in the majority of the patients in
this study. There are many published reports suggesting that an
open artery may well influence ventricular remodeling both by
curtailing infarct expansion and by potentially influencing
remodeling in viable myocardium (47,48). Alternatively, the
beneficial effect of ACE inhibitor therapy may be in the
vasculature by preventing endothelial dysfunction, progression
of coronary atherosclerosis and MI (49). This potential mech-
anism is currently being tested in clinical trials to determine
whether ACE inhibitors should be continued long term in
patients with normal or near normal LVEFs after MI and in
patients with documented coronary atherosclerosis with no
prior history of MI.
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